真实世界FIRST注册研究中类风湿关节炎患者抗IL-6受体抑制剂与JAK抑制剂的比较
本研究基于真实世界FIRST注册数据,采用倾向评分逆概率治疗加权比较抗IL-6受体抑制剂(IL-6Ri)与JAK抑制剂(JAKis)治疗类风湿关节炎26周的疗效与安全性。JAKis组CDAI缓解率和感染发生率均高于IL-6Ri组;对一种bDMARD无效者两药CDAI缓解率无显著差异,对至少两种bDMARD无效者JAKis组CDAI缓解率更高。
要点
- JAKis组26周CDAI缓解率和感染发生率均高于IL-6Ri组。
- 对一种bDMARD无效者,JAKis组CDAI缓解率29.1% vs IL-6Ri组21.8%(P=0.21),无显著差异。
- 对至少两种bDMARD无效者,JAKis组26周CDAI缓解率高于IL-6Ri组。
核心结论
- 对一种bDMARD无效的RA患者,IL-6Ri在疗效与安全性平衡上优于JAKis;对多种bDMARD无效者,JAKis可能更合适。
研究设计与样本
- 基于真实世界FIRST注册数据,采用倾向评分逆概率治疗加权(PS-IPTW)比较JAKis与IL-6Ri治疗26周的疗效与安全性。
主要发现
- 26周CDAI缓解率和感染发生率JAKis组均高于IL-6Ri组。
- 对一种bDMARD无效者,26周CDAI缓解率JAKis组29.1% vs IL-6Ri组21.8%(P=0.21),无显著差异。
- 对至少两种bDMARD无效者,26周CDAI缓解率JAKis组高于IL-6Ri组。
- CDAI轨迹经增长混合模型分为四类。
- 对单一bDMARD无效者IL-6Ri疗效优于对多种bDMARD无效者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A molecular-targeted drug that is suitable as the second choice for patients with rheumatoid arthritis (RA) who show an inadequate response to the first biological disease-modifying antirheumatic drug (bDMARD) is unknown. This study aimed to analyse the efficacy and safety of interleukin-6 receptor (IL-6Ri) and Janus kinase inhibitors (JAKis), often selected as molecular-targeted drugs for second or subsequent treatments. METHODS: The efficacy and safety of JAKis and IL-6Ri were compared using propensity score-based inverse probability of treatment weighting (PS-IPTW) using propensity scores after 26 weeks of therapy in patients with RA. RESULTS: The remission rate at week 26, determined by the clinical disease activity index (CDAI), and the incidence of infection were higher in the JAKis than in the IL-6Ri group. The CDAI trajectories were divided into four according to the growth mixture modeling. IL-6Ri demonstrated greater efficacy in RA patients with ineffective to single bDMARD therapy compared with those with multiple ineffective bDMARDs. In patients who failed to respond to one bDMARD, there was no significant difference in the CDAI remission rate at week 26 between the JAKis (29.1%) and IL-6Ri (21.8%) groups (P = 0.21). However, for patients who did not respond to at least two bDMARDs, the CDAI remission rate at week 26 was higher in the JAKis than in the IL-6Ri group. CONCLUSIONS: IL-6Ri offers a superior balance of efficacy and safety compared with JAKis for RA patients unresponsive to one bDMARD. However, JAKis may suit patients who do not respond to multiple bDMARDs.
引用
- Miyazaki Y, Nakayamada S, Tanaka H, et al. Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry. Rheumatology (Oxford). 2025. PMID: 38889301. doi:10.1093/rheumatology/keae334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。